Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.50 |
| ▸ | KDM5A | P29375 | 8/20 | 0.50 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804218 | 0.86 | NOD1 (0.50) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL4541602 | 0.83 | NOS1 (0.51) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL1376620 | 0.79 | NOD1 (0.54) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL20816296 | 0.79 | NOD1 (0.54) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL22499943 | 0.79 | SLC1A2 (0.47) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| D-Glutamate SCHEMBL27621314 | 0.78 | GRIK1 (0.72) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL10387789 | 0.77 | KDM4C (0.64) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL29049662 | 0.77 | KDM4C (0.69) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL31749305 | 0.77 | KDM4C (0.69) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL8450995 | 0.77 | KDM4C (0.69) | KDM4CKDM5APHF8KDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160319322-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | HAMP, SLC40A1, FTH1 | KDM4C 2436/4885KDM5A 2574/4885PHF8 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.